RARB: Retinoic acid receptor beta
Receptor for retinoic acid.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on RARB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Tamibarotene | Approved | Rege Nephro Co., Ltd. | Small molecule | AgonistRetinoic acid receptor beta agonist | 3 |
| The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial) | Tamibarotene | Phase 2 | Recruiting | Nagoya University | Oct 2, 2026 |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | Tamibarotene | Phase 2 | Recruiting | Nagoya University | May 21, 2025 |
| Study of Tamibarotene in Patients With ADPKD | Tamibarotene | Phase 2 | Active, not recruiting | Rege Nephro Co., Ltd. | Mar 4, 2024 |
- Microphthalmia, syndromic 120.78
- Microphthalmia, syndromic 90.63
- Acne0.61
- Acute promyelocytic leukemia0.60
- Psoriasis0.59
- Psoriasis vulgaris0.57
- Hyperpigmentation of the skin0.54
- Freckles0.54
- Neoplasm0.49
- Microphthalmia0.47
- Kaposi's sarcoma0.47
- Open-angle glaucoma0.46
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2008, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10826, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets